Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2014 3
2015 3
2016 2
2018 1
2019 2
2021 5
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.
Turkova A, White E, Kekitiinwa AR, Mumbiro V, Kaudha E, Liberty A, Ahimbisibwe GM, Moloantoa T, Srirompotong U, Mosia NR, Puthanakit T, Kobbe R, Fortuny C, Kataike H, Bbuye D, Na-Rajsima S, Coelho A, Lugemwa A, Bwakura-Dangarembizi MF, Klein N, Mujuru HA, Kityo C, Cotton MF, Ferrand RA, Giaquinto C, Rojo P, Violari A, Gibb DM, Ford D; ODYSSEY trial team. Turkova A, et al. Lancet Child Adolesc Health. 2023 Oct;7(10):718-727. doi: 10.1016/S2352-4642(23)00164-5. Epub 2023 Aug 8. Lancet Child Adolesc Health. 2023. PMID: 37562418 Free article. Clinical Trial.
Personalised dosing: Printing a dose of one's own medicine.
Alomari M, Mohamed FH, Basit AW, Gaisford S. Alomari M, et al. Among authors: mohamed fh. Int J Pharm. 2015 Oct 30;494(2):568-577. doi: 10.1016/j.ijpharm.2014.12.006. Epub 2014 Dec 10. Int J Pharm. 2015. PMID: 25498157 Review.
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Amuge P, Lugemwa A, Wynne B, Mujuru HA, Violari A, Kityo CM, Archary M, Variava E, White E, Turner RM, Shakeshaft C, Ali S, Nathoo KJ, Atwine L, Liberty A, Bbuye D, Kaudha E, Mngqibisa R, Mosala M, Mumbiro V, Nanduudu A, Ankunda R, Maseko L, Kekitiinwa AR, Giaquinto C, Rojo P, Gibb DM, Turkova A, Ford D; ODYSSEY Trial Team. Amuge P, et al. Lancet HIV. 2022 Sep;9(9):e638-e648. doi: 10.1016/S2352-3018(22)00163-1. Lancet HIV. 2022. PMID: 36055295 Free PMC article. Clinical Trial.
Incidence of hip fracture in Saudi Arabia and the development of a FRAX model.
Saleh YAL, Sulimani RA, Alomary S, Alnajjar YI, Vandenput L, Liu E, Lorentzon M, Harvey NC, McCloskey EV, Johansson H, Kanis JA; Saudi FRAX Study Group. Saleh YAL, et al. Arch Osteoporos. 2022 Apr 2;17(1):56. doi: 10.1007/s11657-022-01085-x. Arch Osteoporos. 2022. PMID: 35366737 Free PMC article.
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A, Lugemwa A, Cressey TR, Musoke P, Variava E, Cotton MF, Archary M, Puthanakit T, Behuhuma O, Kobbe R, Welch SB, Bwakura-Dangarembizi M, Amuge P, Kaudha E, Barlow-Mosha L, Makumbi S, Ramsagar N, Ngampiyaskul C, Musoro G, Atwine L, Liberty A, Musiime V, Bbuye D, Ahimbisibwe GM, Chalermpantmetagul S, Ali S, Sarfati T, Wynne B, Shakeshaft C, Colbers A, Klein N, Bernays S, Saïdi Y, Coelho A, Grossele T, Compagnucci A, Giaquinto C, Rojo P, Ford D, Gibb DM; ODYSSEY Trial Team. Turkova A, et al. N Engl J Med. 2021 Dec 30;385(27):2531-2543. doi: 10.1056/NEJMoa2108793. N Engl J Med. 2021. PMID: 34965338 Free PMC article. Clinical Trial.
Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease.
Blauwendraat C, Reed X, Kia DA, Gan-Or Z, Lesage S, Pihlstrøm L, Guerreiro R, Gibbs JR, Sabir M, Ahmed S, Ding J, Alcalay RN, Hassin-Baer S, Pittman AM, Brooks J, Edsall C, Hernandez DG, Chung SJ, Goldwurm S, Toft M, Schulte C, Bras J, Wood NW, Brice A, Morris HR, Scholz SW, Nalls MA, Singleton AB, Cookson MR; COURAGE-PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson’s Disease) Consortium, the French Parkinson’s Disease Consortium, and the International Parkinson’s Disease Genomics Consortium (IPDGC). Blauwendraat C, et al. JAMA Neurol. 2018 Nov 1;75(11):1416-1422. doi: 10.1001/jamaneurol.2018.1885. JAMA Neurol. 2018. PMID: 30039155 Free PMC article.
Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes.
Ponirakis G, Al-Janahi I, Elgassim E, Gad H, Petropoulos IN, Khan A, Ali H, Siddique MA, Gul W, Ferdousi M, Kalteniece A, Mohamed FF, Ahmed LH, Dakroury Y, El Shewehy AM, Al-Mohamedi A, AlMarri F, Homssi M, Qazi M, Hadid NH, Al-Khayat F, Mahfoud ZR, Azmi S, Alam U, Zirie MA, Al-Ansari Y, Jayyousi A, Rigby AS, Kilpatrick ES, Atkin SL, Malik RA. Ponirakis G, et al. Among authors: mohamed ff. J Diabetes Investig. 2022 Oct;13(10):1703-1710. doi: 10.1111/jdi.13864. Epub 2022 Jun 20. J Diabetes Investig. 2022. PMID: 35652859 Free PMC article.
19 results